Get ready for a deep dive into colchicine and cardiovascular disease! We’ll examine the RCT data, and then pivot to discuss ...

Gout flares are commonly treated with colchicine, which can provoke GI side effects, particularly diarrhea. The Acute Gout Flare Receiving Colchicine Evaluation (AGREE) trial investigated the efficacy ...

May 7, 2010 — The US Food and Drug Administration (FDA) has issued new dosing guidelines for colchicine (Colcrys tablets; URL Pharma, Inc) when used with protease inhibitors in HIV patients. According ...

Colcrys, a new colchicine formulation, has received marketing clearance for the prevention of gout flares. The FDA first approved the oral medication in July for the treatment of acute gout flares ...

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today ...

Please provide your email address to receive an email when new articles are posted on . A 0.5 mg dose of colchicine has been approved for use in high-risk patients who have inflammatory risk. The dose ...

The FDA approved colchicine (Lodoco) for cardiovascular prevention in adults with established atherosclerotic disease or multiple risk factors, making it the first anti-inflammatory medicine with such ...

WOBURN, Mass.--(BUSINESS WIRE)--ROMEG Therapeutics, an innovative drug development company focused on alternative formulations to better meet clinical and patient needs, today announced that the U.S.

PHILADELPHIA – New data show that low-dose colchicine (Colcrys TM) rapidly controls acute gout flares. The results, which were presented at the 2009 Annual Scientific Meeting of the American College ...

For this study, investigators initially screened 813 patients, each with a known history of gout. Of this group, 575 met the inclusion criteria that included age ≥ 18 years, a confirmed diagnosis of ...

Please provide your email address to receive an email when new articles are posted on . Secondary prevention of CVD with colchicine is a major focus for the cardiology community, especially after ...

DUBLIN, July 2, 2018 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping an authorized generic ...